Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer. Mr. Robertson brings more than twenty years of experience with corporate strategy, business operations, capital raising and M&A.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240103822562/en/

Star CFO-CBO Scott Robertson (Photo: Business Wire)

“We are excited to welcome Scott to the Star leadership team during this time of significant growth,” said Adam Rosenthal, PhD, Chief Executive Officer and Founder of Star Therapeutics. “His extensive experience as a proven operator with a background in venture capital and investment banking will be invaluable as we continue to replicate our success in forming new portfolio companies and advancing them into the clinic.”

Prior to joining Star Therapeutics, Mr. Robertson served as Chief Business Officer and Chief Financial Officer of DICE Therapeutics, where he contributed to corporate strategy, raised more than $700 million in private and public financings, and led the business development interactions that resulted in the acquisition of the company by Eli Lilly for $2.4 billion. Previously, at DuPont, he served as Business Development Director for DuPont Pioneer, with responsibility for mergers and acquisitions and strategic partnerships, and Portfolio Manager for DuPont Ventures. Prior to joining DuPont, Mr. Robertson was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and earlier in his career, he was a member of the healthcare investment banking teams at Merrill Lynch & Co. and Thomas Weisel Partners. He holds a BS in Business Administration from the University of Southern California and an MBA from the Haas School of Business at the University of California, Berkeley.

“I’m very excited to join the Star Therapeutics team at a time of great momentum with its proven approach for translating novel biology into first-in-class antibody therapies. I look forward to contributing my expertise to enable the company to deliver a wide range of powerful new medicines to patients,” said Mr. Robertson.

About Star Therapeutics

Star Therapeutics is a biotechnology company that interrogates areas of novel biology to develop life-changing therapies for as many patients as possible, initially addressing unmet needs in hematology and immunology. The company’s engine for innovation starts with identifying multiple diseases that share a common biology and then discovering novel therapeutics that can treat numerous diseases with a single therapy. Star consists of a constellation of companies, each focused on a specific area of biology with first-in-class therapies. Star is backed by leading life sciences investors and located in South San Francisco. For more information, please visit www.star-therapeutics.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103822562/en/